The growing acceptance of psychedelics in mainstream medicine is being driven by research, funding, and influential backers, despite financial concerns ...
LumiraDx, a UK-based diagnostics company, faces delisting from Nasdaq due to non-compliance with listing requirements. Its appeal has been withdrawn ...